Il1rap antibodies and uses thereof

A method of treating a disease in a subject, comprising the step of administering to the subject a composition comprising an effective amount of the anti-IL1RAP antibody, said anti-IL1RAP antibody comprising three complementarity determining regions (CDRs) on a heavy chain (HCDR1, HCDR2, and HCDR3) and three CDRs on a light chain (LCDR1, LCDR2, and LCDR3), wherein

• (a) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:
• 35, 50, and 65, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:
• 77, 90, and 102;
• or
• (b) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:33, 46 and 62, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:74, 87, and 99;
• or
• (c) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:33, 47, and 62, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:75, 88, and 100;
• or
• (d) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:34, 48, and 63, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:76, 89, and 101;
• or
• (e) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:35, 4,9 and 64, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:77, 90, and 102;
• or
• (f) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:
• 33, 45, and 61, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:
• 73, 87, and 98;
• or
• (g) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:35, 51, and 64, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:77, 90, and 102;
• or
• (h) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:36, 50, and 64, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:78, 90, and 102;
• or
• (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:37, 52, and 66, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:79, 91, and 103;
• or
• (j) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:38, 53, and 67, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:80, 92, and 104;
• or
• (k) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:39, 54, and 67, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:81, 92, and 104;
• or
• (l) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:40, 55, and 68, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:82, 93, and 105;
• or
• (m) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:41, 56, and 69, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:83, 94, and 106;
• or
• (n) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:42, 57, and 70, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:84, 95, and 107;
• or
• (o) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:43, 58, and 70, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:85, 96, and 107;
• or
• (p) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:44, 59, and 71, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:73, 87, and 98;
• or
• (q) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:44, 60, and 72, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:86, 97, and 108.